ALGS Relative Valuation
ALGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALGS is overvalued; if below, it's undervalued.
Historical Valuation
Aligos Therapeutics Inc (ALGS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 44.35 is considered Undervalued compared with the five-year average of -2.96. The fair price of Aligos Therapeutics Inc (ALGS) is between 68.91 to 75.94 according to relative valuation methord. Compared to the current price of 9.65 USD , Aligos Therapeutics Inc is Undervalued By 86%.
Relative Value
Fair Zone
68.91-75.94
Current Price：9.65
86%
Undervalued
-1.17
PE
1Y
3Y
5Y
0.36
EV/EBITDA
Aligos Therapeutics Inc. (ALGS) has a current EV/EBITDA of 0.36. The 5-year average EV/EBITDA is -3.38. The thresholds are as follows: Strongly Undervalued below -17.56, Undervalued between -17.56 and -10.47, Fairly Valued between 3.71 and -10.47, Overvalued between 3.71 and 10.79, and Strongly Overvalued above 10.79. The current Forward EV/EBITDA of 0.36 falls within the Historic Trend Line -Fairly Valued range.
0.37
EV/EBIT
Aligos Therapeutics Inc. (ALGS) has a current EV/EBIT of 0.37. The 5-year average EV/EBIT is -3.34. The thresholds are as follows: Strongly Undervalued below -17.43, Undervalued between -17.43 and -10.39, Fairly Valued between 3.71 and -10.39, Overvalued between 3.71 and 10.75, and Strongly Overvalued above 10.75. The current Forward EV/EBIT of 0.37 falls within the Historic Trend Line -Fairly Valued range.
44.35
PS
Aligos Therapeutics Inc. (ALGS) has a current PS of 44.35. The 5-year average PS is 61.81. The thresholds are as follows: Strongly Undervalued below -244.44, Undervalued between -244.44 and -91.31, Fairly Valued between 214.93 and -91.31, Overvalued between 214.93 and 368.06, and Strongly Overvalued above 368.06. The current Forward PS of 44.35 falls within the Historic Trend Line -Fairly Valued range.
-0.62
P/OCF
Aligos Therapeutics Inc. (ALGS) has a current P/OCF of -0.62. The 5-year average P/OCF is -4.85. The thresholds are as follows: Strongly Undervalued below -21.56, Undervalued between -21.56 and -13.20, Fairly Valued between 3.50 and -13.20, Overvalued between 3.50 and 11.86, and Strongly Overvalued above 11.86. The current Forward P/OCF of -0.62 falls within the Historic Trend Line -Fairly Valued range.
-0.59
P/FCF
Aligos Therapeutics Inc. (ALGS) has a current P/FCF of -0.59. The 5-year average P/FCF is -5.31. The thresholds are as follows: Strongly Undervalued below -25.75, Undervalued between -25.75 and -15.53, Fairly Valued between 4.91 and -15.53, Overvalued between 4.91 and 15.13, and Strongly Overvalued above 15.13. The current Forward P/FCF of -0.59 falls within the Historic Trend Line -Fairly Valued range.
Aligos Therapeutics Inc (ALGS) has a current Price-to-Book (P/B) ratio of 0.78. Compared to its 3-year average P/B ratio of 1.14 , the current P/B ratio is approximately -31.60% higher. Relative to its 5-year average P/B ratio of 2.85, the current P/B ratio is about -72.56% higher. Aligos Therapeutics Inc (ALGS) has a Forward Free Cash Flow (FCF) yield of approximately -141.56%. Compared to its 3-year average FCF yield of -105.05%, the current FCF yield is approximately 34.76% lower. Relative to its 5-year average FCF yield of -76.95% , the current FCF yield is about 83.98% lower.
0.78
P/B
Median3y
1.14
Median5y
2.85
-141.56
FCF Yield
Median3y
-105.05
Median5y
-76.95
Competitors Valuation Multiple
The average P/S ratio for ALGS's competitors is 1320.13, providing a benchmark for relative valuation. Aligos Therapeutics Inc Corp (ALGS) exhibits a P/S ratio of 44.35, which is -96.64% above the industry average. Given its robust revenue growth of -41.61%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ALGS decreased by 62.60% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.52K to -4.26K.
The secondary factor is the Revenue Growth, contributed -41.61%to the performance.
Overall, the performance of ALGS in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
ZENV
Zenvia Inc
0.97USD
-2.02%
EBMT
Eagle Bancorp Montana Inc
20.18USD
3.38%
VOXR
Vox Royalty Corp
4.6USD
-1.08%
LPSN
LivePerson Inc
4.03USD
0.25%
QRHC
Quest Resource Holding Corp
1.96USD
-4.39%
VERI
Veritone Inc
4.8USD
-0.21%
BSET
Bassett Furniture Industries Inc
16.4USD
2.44%
NTIC
Northern Technologies International Corp
8.69USD
-0.57%
SENEB
Seneca Foods Corp
114.21USD
3.24%
Frequently Asked Questions
Is Aligos Therapeutics Inc (ALGS) currently overvalued or undervalued?
Aligos Therapeutics Inc (ALGS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 44.35 is considered Undervalued compared with the five-year average of -2.96. The fair price of Aligos Therapeutics Inc (ALGS) is between 68.91 to 75.94 according to relative valuation methord. Compared to the current price of 9.65 USD , Aligos Therapeutics Inc is Undervalued By 86.00% .
What is Aligos Therapeutics Inc (ALGS) fair value?
ALGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Aligos Therapeutics Inc (ALGS) is between 68.91 to 75.94 according to relative valuation methord.
How does ALGS's valuation metrics compare to the industry average?
The average P/S ratio for ALGS's competitors is 1320.13, providing a benchmark for relative valuation. Aligos Therapeutics Inc Corp (ALGS) exhibits a P/S ratio of 44.35, which is -96.64% above the industry average. Given its robust revenue growth of -41.61%, this premium appears unsustainable.
What is the current P/B ratio for Aligos Therapeutics Inc (ALGS) as of Jan 08 2026?
As of Jan 08 2026, Aligos Therapeutics Inc (ALGS) has a P/B ratio of 0.78. This indicates that the market values ALGS at 0.78 times its book value.
What is the current FCF Yield for Aligos Therapeutics Inc (ALGS) as of Jan 08 2026?
As of Jan 08 2026, Aligos Therapeutics Inc (ALGS) has a FCF Yield of -141.56%. This means that for every dollar of Aligos Therapeutics Inc’s market capitalization, the company generates -141.56 cents in free cash flow.
What is the current Forward P/E ratio for Aligos Therapeutics Inc (ALGS) as of Jan 08 2026?
As of Jan 08 2026, Aligos Therapeutics Inc (ALGS) has a Forward P/E ratio of -1.17. This means the market is willing to pay $-1.17 for every dollar of Aligos Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Aligos Therapeutics Inc (ALGS) as of Jan 08 2026?
As of Jan 08 2026, Aligos Therapeutics Inc (ALGS) has a Forward P/S ratio of 44.35. This means the market is valuing ALGS at $44.35 for every dollar of expected revenue over the next 12 months.